The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
TP53 and KRAS Mutation Load and Types in Lung Cancers in Relation to Tobacco Smoke: Distinct Patterns in Never, Former, and Current Smokers
Open accessPublished version of a preprint
Abstract
TP53 mutations are common in lung cancers of smokers, with high prevalence of G:C-to-T:A transversions generally interpreted as mutagen fingerprints of tobacco smoke. In this study, TP53 (exons 5-9) and KRAS (codon 12) were analyzed in primary lung tumors of never (n = 40), former (n = 27), and current smokers (n = 64; mainly heavy smokers). Expression of p53, cyclooxygenase-2 (Cox-2), and nitrotyrosine (N-Tyr), a marker of protein damage by nitric oxide, were analyzed by immunohistochemistry. TP53 mutations were detected in 47.5% never, 55.6% former, and 77.4% current smokers. The relative risk for mutation increased with tobacco consumption (Plinear trend < 0.0001). G:C-to-T:A transversions (P = 0.06, current versus never smokers) and A:T-to-G:C transitions (P = 0.03, former versus never smokers) were consistently associated with smoking. In contrast, G:C-to-A:T transitions were associated with never smoking (P = 0.02). About half of mutations in current smokers fell within a particular domain of p53 protein, suggesting a common structural effect. KRAS mutations, detected in 20 of 131 (15.3%) cases, were rare in squamous cell carcinoma compared with adenocarcinoma [relative risk (RR), 0.2; 95% confidence interval (95% CI), 0.07-1] and were more frequent in former smokers than in other categories. No significant differences in Cox-2 expression were found between ever and never smokers. However, high levels of N-Tyr were more common in never than ever smokers (RR, 10; 95% CI, 1.6-50). These results support the notion that lung tumorigenesis proceeds through different molecular mechanisms according to smoking status. In never smokers, accumulation of N-Tyr suggests an etiology involving severe inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unlike other clinically actionable genomic alterations found in NSCLCs (such as EGFR and ALK aberrations), KRAS mutations, particularly KRASG12C and KRASG12V, are strongly associated with smoking29–31.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans
Carter, R. L. (1980) · Journal of Clinical Pathology · doi:10.1136/jcp.33.1.98-b · Cited by 3,455
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Preferential Formation of Benzo[ a ]pyrene Adducts at Lung Cancer Mutational Hotspots in P53
Denissenko, M. F., Pao, A., Tang, M.-S., & Pfeifer, G. P. (1996) · Science · doi:10.1126/science.274.5286.430 · Cited by 1,650
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers
Pfeifer, G. P., Denissenko, M. F., Olivier, M., Tretyakova, N. Y., Hecht, S. S., & Hainaut, P. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205803 · Cited by 1,107
Self-citationBiochemistry, Biology, and Carcinogenicity of Tobacco-Specific N -Nitrosamines
Hecht, S. S. (1998) · Chemical Research in Toxicology · doi:10.1021/tx980005y · Cited by 1,074
Molecular Damage in the Bronchial Epithelium of Current and Former Smokers
Wistuba, I. I., Virmani, A. K., Gazdar, A. F., Lam, S. C., LeRiche, J., Behrens, C., Fong, K. M., Samet, J. M., Srivastava, S., & Minna, J. D. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.18.1366 · Cited by 487
Hainaut, P. (2001) · Carcinogenesis · doi:10.1093/carcin/22.3.367 · Cited by 375
Self-citationClinical significance of ras oncogene activation in human lung cancer
Therapy, E. (1993) · Lung Cancer · doi:10.1016/0169-5002(93)90536-7 · Cited by 361
Research works printed but not linked: 1
- Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002; 21: 7435–51. · DOI
Cited by
Sorted by citations
Items 101–200 of 272
Selumetinib for the treatment of non-small cell lung cancer
Casaluce, F., Sgambato, A., Maione, P., Sacco, P. C., Santabarbara, G., & Gridelli, C. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1351543 · Cited by 33
Daylan, A. E. C., Miao, E., Tang, K., Chiu, G., & Cheng, H. (2023) · Lung · doi:10.1007/s00408-023-00661-3 · Cited by 32
Yamaguchi, F., Kugawa, S., Tateno, H., Kokubu, F., & Fukuchi, K. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.08.014 · Cited by 33
Paris, C., Clément-Duchêne, C., Vignaud, J.-M., Gislard, A., Stoufflet, A., Bertrand, O., Thiberville, L., Grosdidier, G., Martinet, Y., Bénichou, J., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.06.007 · Cited by 31
Self-citationLee, Y. J., Shim, H. S., Kang, Y. A., Hong, S. J., Kim, H. K., Kim, H., Kim, Y. S., Choi, S. H., Kim, J.-H., & Cho, B. C. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0853-4 · Cited by 29
Ito, K., Yano, T., Morodomi, Y., Yoshida, T., Kohno, M., Haro, A., Shikada, Y., Okamoto, T., Maruyama, R., & Maehara, Y. (2012) · PubMed · Cited by 29
Reactive X (where X = O, N, S, C, Cl, Br, and I) species nanomedicine
Wang, K., Mao, W., Song, X., Chen, M., Feng, W., Peng, B., & Chen, Y. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00435f · Cited by 28
Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer
Gong, H. C., Wang, S., Mayer, G., Chen, G., Leesman, G. D., Singh, S., & Beer, D. G. (2011) · International Journal of Proteomics · doi:10.1155/2011/215496 · Cited by 28
Carcinogenic Polycyclic Aromatic Hydrocarbons
Murray, J. R., & Penning, T. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95691-5 · Cited by 28
Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer
SINGH, S. P., Saxena, S., Sharma, H., Paudel, K. R., Chakraborty, A., MacLoughlin, R. J., Oliver, B. G. G., Gupta, G., Negi, P., Singh, S. K., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155222 · Cited by 26
Hu, Y., & Chen, G. (2015) · Oncology Letters · doi:10.3892/ol.2015.3462 · Cited by 27
Reamon-Buettner, S. M., & Borlak, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0967 · Cited by 27
Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non–small-cell Lung Cancer
Mathiot, L., Nigen, B., Goronflot, T., Hiret, S., Doucet, L. S., Tostivint, E. P., Bennouna, J., Denis, M. G., Herbreteau, G., & Raimbourg, J. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.12.004 · Cited by 26
Arrieta, O. G., Martínez-Barrera, L. M., Treviño, S. C., Guzman, E., Castillo-González, P., Ríos-Trejo, M. Á., Flores‐Estrada, D., Téllez, E. A., Gonzalez, C., Cruz-Vargas, J. A. D. L., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818026f6 · Cited by 26
Ho, H., Kao, H., Yeh, Y., & Chou, T. (2019) · Diagnostic Pathology · doi:10.1186/s13000-019-0840-2 · Cited by 26
Szymańska, K., Levi, J. E., Menezes, A. M. B., Wünsch‐Filho, V., Eluf‐Neto, J., Koifman, S., Matos, E., Daudt, A. W., Curado, M. P., Villar, S., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp212 · Cited by 26
Self-citationMao, W., Wen, Y., Lei, H., Lu, R., Wang, S., Wang, Y., Chen, R., Gu, Y., Zhu, L., Abhange, K. K., et al. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b03064 · Cited by 25
Okazaki, I., Ishikawa, S., & Sohara, Y. (2014) · PubMed · Cited by 26
Anna, L., Holmila, R. J., Kovács, K., Győrffy, E., Győri, Z., Segesdi, J., Minárovits, J., Soltész, I., Kostic, S., Csekeõ, A., et al. (2009) · Mutagenesis · doi:10.1093/mutage/gep031 · Cited by 24
Castiglione, R., Alidousty, C., Holz, B., Wagener‐Ryczek, S., Baar, T., Heydt, C., Binot, E., Zupp, S., Kron, A., Wolf, J., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0182-8 · Cited by 24
Sueoka, N., Sato, A., Eguchi, H., Komiya, K., Sakuragi, T., Mitsuoka, M., Satoh, T., Hayashi, S., Nakachi, K., & Sueoka, E. (2006) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-006-0144-2 · Cited by 24
Kunz, M., Göttlich, C., Walles, T., Nietzer, S., Dandekar, G., & Dandekar, T. (2017) · Tumor Biology · doi:10.1177/1010428317706430 · Cited by 23
Liang, Y., Thakur, A., Gao, L., Wang, T., Zhang, S., Ren, H., Meng, J., Geng, T., Jin, T., & Chen, M. (2014) · Tumor Biology · doi:10.1007/s13277-014-2508-6 · Cited by 23
SMOKING-RELATED DNA ADDUCTS AS POTENTIAL DIAGNOSTIC MARKERS OF LUNG CANCER: NEW PERSPECTIVES
Grigoryeva, E. S., Kokova, D. A., Gratchev, A. N., Cherdyntsev, E., Buldakov, M. A., Kzhyshkowska, J. G., & Чердынцева, Н. В. (2015) · Experimental Oncology · doi:10.31768/2312-8852.2015.37(1):5-12 · Cited by 23
Tomasini, P., Mascaux, C., Jao, K., Labbe, C., Kamel-Reid, S., Stockley, T., Hwang, D. M., Leighl, N. B., Liu, G., Bradbury, P. A., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.12.009 · Cited by 22
Takeshita, M., Koga, T., Takayama, K., Kouso, H., Nishimura‐Ikeda, Y., Yoshino, I., Maehara, Y., Nakanishi, Y., & Sueishi, K. (2008) · International Journal of Cancer · doi:10.1002/ijc.23673 · Cited by 22
Gadgeel, S. M., Miao, J., Riess, J. W., Moon, J., Mack, P. C., Gerstner, G. J., Burns, T. F., Taj, A., Akerley, W., Dragnev, K. H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3947 · Cited by 22
Molecular changes in smoking-related lung cancer
Begum, S. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.84 · Cited by 22
Zhang, L., Gallup, M., Zlock, L. T., Finkbeiner, W. E., & McNamara, N. A. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.02.008 · Cited by 21
Singh, V., Guleria, P., Malik, P. S., Mohan, A., Thulkar, S. P., Pandey, R. M., Luthra, K., Arava, S. K., Ray, R., & Jain, D. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.12.003 · Cited by 20
Planchard, D., Dômont, J., Clermont, E., Monnet, I., Trédaniel, J., Caliandro, R., Validire, P., Besse, B., Soria, J., & Fouret, P. J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn785 · Cited by 20
EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer
DONG, Y., Ren, W., QI, J., Jin, B., Li, Y., Tao, H.-Q., XU, R., Li, Y., Zhang, Q., & Han, B. (2016) · Oncology Letters · doi:10.3892/ol.2016.4235 · Cited by 19
Lee, B., Lee, B., Han, G., Kwon, M. J., Han, J., & Choi, Y. (2014) · Journal of Pathology and Translational Medicine · doi:10.4132/koreanjpathol.2014.48.2.100 · Cited by 19
Tafe, L. J. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000244 · Cited by 19
Impact of smoking amount on clinicopathological features and survival in non-small cell lung cancer
Ban, W. H., Yeo, C. D., Han, S., Kang, H. S., Park, C. K., Kim, J. S., Kim, J. W., Kim, S. J., Lee, S. H., & Kim, S. K. (2020) · BMC Cancer · doi:10.1186/s12885-020-07358-3 · Cited by 19
New experimental data linking secondhand smoke exposure to lung cancer in nonsmokers
Kim, S., Yoon, J., Tommasi, S., & Nia, A. B. (2012) · The FASEB Journal · doi:10.1096/fj.11-199984 · Cited by 19
Hong, H. L., Dunnick, J. K., Herbert, R., Devereux, T. R., Kim, Y., & Sills, R. C. (2006) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20197 · Cited by 19
Jiang, Y., Mingard, C., Huber, S. M., Takhaveev, V., McKeague, M., Kizaki, S., Schneider, M., Ziegler, N., Hürlimann, V., Hoeng, J., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01100 · Cited by 19
Mutation of TP53 and Alteration of p14arf Expression in EGFR- and KRAS-Mutated Lung Adenocarcinomas
Cortot, A. B., Younes, M., Martel-Planche, G., Guibert, B., Isaac, S., Souquet, P.-J., Commo, F., Girard, P., Fouret, P. J., Brambilla, E. M., et al. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.08.003 · Cited by 18
Self-citationLim, E. H., Zhang, S.-L., Yu, K., Nga, M., Ahmed, D. A., Agasthian, T., Wong, P.-S., Chua, G. C., Wong, D., Tan, L., et al. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000268671.49378.c2 · Cited by 18
Uramoto, H., So, T., Nagata, Y., Kuroda, K., Shigematsu, Y., Baba, T., So, T., Takenoyama, M., Hanagiri, T., & Yasumoto, K. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e0b993 · Cited by 17
Histological Evaluation of the Effect of Smoking on Peripheral Small Adenocarcinomas of the Lung
Maeshima, A. M., Tochigi, N., Tsuta, K., Asamura, H., & Matsuno, Y. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31817c60ae · Cited by 17
Lung cancer incidence in never smokers: Genetic and gender basis
Peddireddy, V. (2016) · Gene Reports · doi:10.1016/j.genrep.2016.06.003 · Cited by 17
Lin, C.-H., Chen, P.-M., Cheng, Y., Chen, C., Yuan, C.-J., & Lee, H. (2012) · Journal of Epidemiology · doi:10.2188/jea.je20120048 · Cited by 16
Genetic Mutation Screen in Early Non–Small-Cell Lung Cancer (NSCLC) Specimens
Bar, J., Damianovich, M., Hout‐Siloni, G., Dar, E., Cohen, Y., Perelman, M., Nun, A. B., Simansky, D. A., Yellin, A., Urban, D., et al. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.11.005 · Cited by 16
Kitahashi, T., Takahashi, M., Yamada, Y., Oghiso, Y., Yokohira, M., Imaida, K., Tsutsumi, M., Takasuka, N., Sügimura, T., & Wakabayashi, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00680.x · Cited by 16
New approaches to assessing the effects of mutagenic agents on the integrity of the human genome
Elespuru, R. K., & Sankaranarayanan, K. (2006) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2006.11.015 · Cited by 17
Hong, H. L., Ton, T.-V. T., Kim, Y., Wakamatsu, N., Clayton, N. P., Chan, P., Sills, R. C., & Lahousse, S. A. (2008) · Toxicologic Pathology · doi:10.1177/0192623308320280 · Cited by 16
The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy
Tufail, M., Gong, K., Ijaz, B., Patel, H. H., Lui, W., Wang, X., & Li, J. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101355 · Cited by 16
Hong, H. L., Hoenerhoff, M. J., Ton, T.-V. T., Herbert, R. A., Kissling, G. E., Hooth, M. J., Behl, M., Witt, K. L., Smith‐Roe, S. L., Sills, R. C., et al. (2015) · Toxicologic Pathology · doi:10.1177/0192623315581192 · Cited by 15
Xing, X., Li, L., Sun, M., Zhu, X., & Feng, Y. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241249168 · Cited by 14
Gonzalez, M., Vignaud, J.-M., Clément-Duchêne, C., Luc, A., Wild, P. P., Bertrand, O., Thiberville, L., Martinet, Y., Bénichou, J., & Paris, C. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318233d7a6 · Cited by 14
Langie, S. A. S., Knaapen, A. M., Ramaekers, C. H. M. A., Theys, J., Brun, J., Godschalk, R., van Schooten, F., Lambin, P., Gray, D. A., Wouters, B. G., et al. (2007) · DNA repair · doi:10.1016/j.dnarep.2007.02.012 · Cited by 14
Exon 19 of EGFR mutation in relation to the CA‐repeat polymorphism in intron 1
Sueoka‐Aragane, N., Imai, K., Komiya, K., Sato, A., Tomimasu, R., Hisatomi, T., Sakuragi, T., Mitsuoka, M., Hayashi, S., Nakachi, K., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00804.x · Cited by 14
Surien, O., Ghazali, A. R., & Masre, S. F. (2019) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/1617 · Cited by 13
Kiso, M., Urabe, Y., Ito, M., Masuda, K., Boda, T., Kotachi, T., Hata, K., Yorita, N., Nagasaki, N., Abduwali, M., et al. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01387-9 · Cited by 13
Baykara, O., Tansarikaya, M., Demirkaya, A., Kaynak, K., Tanju, S., Toker, A., & Buyru, N. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.829 · Cited by 13
Analysis of Fifty Hotspot Mutations of Lung Squamous Cell Carcinoma in Never-smokers
Lee, H. Y., Lee, S., Won, J., Lee, D. S., Kwon, N., Choi, S. M., Lee, J., Lee, C., Lee, S., Yim, J., et al. (2017) · Journal of Korean Medical Science · doi:10.3346/jkms.2017.32.3.415 · Cited by 13
Ton, T.-V. T., Hong, H. L., Devereux, T. R., Melnick, R. L., Sills, R. C., & Kim, Y. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.04.015 · Cited by 13
Duan, W., Gao, L., Wu, X., Hade, E. M., Gao, J., Ding, H., Barsky, S. H., Otterson, G. A., & Villalona-Calero, M. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005563 · Cited by 13
A Functional Genomics Review of Non-Small-Cell Lung Cancer in Never Smokers
Hamouz, M., Hammouz, R. Y., Bajwa, M. A., Alsayed, A. W., Orzechowska, M., & Bednarek, A. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713314 · Cited by 12
Exploring lung cancer microenvironment: pathways and nanoparticle-based therapies
Arandhara, A., Bhuyan, P., & Das, B. K. (2025) · Discover Oncology · doi:10.1007/s12672-025-01902-y · Cited by 12
Celsi, F., Crovella, S., de Moura, R. R., Schneider, M., Vita, F., Finotto, L., Zabucchi, G., Zacchi, P., & Borelli, V. (2019) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2019.1694612 · Cited by 13
A phylogenetic approach to study the evolution of somatic mutational processes in cancer
Miura, S., Vu, T., Choi, J., Townsend, J. P., Karim, S., & Kumar, S. (2022) · Communications Biology · doi:10.1038/s42003-022-03560-0 · Cited by 12
Tekpli, X., Landvik, N. E., Skaug, V., Gulsvik, A., Haugen, A., & Zienolddiny, S. (2012) · International Journal of Cancer · doi:10.1002/ijc.27870 · Cited by 12
Amicarelli, G., Adlerstein, D., Shehi, E., Wang, F., & Makrigiorgos, G. M. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.068817 · Cited by 12
Tan, C., Xu, H., Zhang, C., Zhang, H., Chen, C., Zhang, W., Sun, X., & Jin, Y. (2011) · Archives of Medical Research · doi:10.1016/j.arcmed.2011.11.008 · Cited by 11
Targeting Angiogenesis from Premalignancy to Metastases
Grandis, J. R., & Argiris, A. E. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0032 · Cited by 11
Short- and long-term survival outcomes among never smokers who developed lung cancer
Nemesure, B. B., Albano, D., & Nemesure, A. (2021) · Cancer Epidemiology · doi:10.1016/j.canep.2021.102042 · Cited by 10
Menzies, G. E., Prior, I. A., Brancale, A., Reed, S. H., & Lewis, P. D. (2021) · BMC Chemistry · doi:10.1186/s13065-021-00777-8 · Cited by 10
An HNSCC syngeneic mouse model for tumor immunology research and preclinical evaluation
Fu, Y., Tian, G., Li, J., Zhang, Z., & Xu, K. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4680 · Cited by 10
Etiologic value of p53 mutation spectra and differences with histology in lung cancers
Shimmyo, T., Okada, A., Hashimoto, T., Kobayashi, Y., Miyagi, Y., Ishikawa, Y., Nakagawa, K., Osada, H., & Tsuchiya, E. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00686.x · Cited by 10
Muallaoğlu, S., Karadeniz, C., Mertsoylu, H., Beşen, A. A., Sezer, A., Sedef, A. M., Köse, F., & Özyılkan, Ö. (2014) · PubMed · Cited by 10
Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma
Sobhani, N., Pittacolo, M., D’Angelo, A., & Marchegiani, G. (2025) · Cancers · doi:10.3390/cancers17040704 · Cited by 12
Hadoux, J., Besse, B., & Planchard, D. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2011.02.001 · Cited by 10
Novel Genetic Associations Between Lung Cancer and Indoor Radon Exposure
Choi, J. R., Koh, S. B., Park, S. Y., Kim, H. R., Lee, H., & Kang, D. R. (2017) · Journal of Cancer Prevention · doi:10.15430/jcp.2017.22.4.234 · Cited by 9
TP53 as clinical marker in head and neck cancer
Peltonen, J. K. (2011) · Cited by 9
Zheng, Z.-R., Ku, H., Chen, K., Chiang, C., Wang, C.-L., Chen, C.-Y., Tsai, C., Huang, M.-S., Yu, C., Chen, J., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1063695 · Cited by 8
Stella, G. M., Bertuccio, F. R., Novy, C., Bortolotto, C., Salzillo, I., Perrotta, F., D’Agnano, V., Conio, V., Arici, V., Cerveri, P., et al. (2025) · Cells · doi:10.3390/cells14161225 · Cited by 7
Shinjo, K., & Kondo, Y. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-612-8_13 · Cited by 8
Adenylosuccinate synthetase 1 gene is a novel target of deletion in lung adenocarcinoma
Miller, J. C., Blake, D. C., & Herzog, C. R. (2009) · Molecular Carcinogenesis · doi:10.1002/mc.20563 · Cited by 7
Could Removing Arsenic from Tobacco Smoke Significantly Reduce Smoker Risks of Lung Cancer?
Cox, L. A. (2008) · Risk Analysis · doi:10.1111/j.1539-6924.2008.01145.x · Cited by 8
The relationship between CHRNA5/A3/B4 gene cluster polymorphisms and lung cancer risk
Yi, X., Li, W., Wang, Y., Chen, X., Ye, F., Sun, G., & Chen, J. (2021) · Medicine · doi:10.1097/md.0000000000024355 · Cited by 8
Li, J., Hu, Y., Wang, Y., Tang, X., Shi, W., & Du, Y. (2014) · The International Journal of Biological Markers · doi:10.5301/jbm.5000075 · Cited by 8
Bioinformatics Analysis Reveals Connection of Squamous Cell Carcinoma and Adenocarcinoma of the Lung
Fan, W., Zhang, X., Guo, H., Zeng, W.-W., Zhang, N., Wan, Q., Xie, W., Cao, J., & Xu, C. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.4.1477 · Cited by 8
Bubendorf, L., Zoche, M., Dafni, U. G., Rüschoff, J. H., Prince, S. S., Marti, N., Stavrou, A., Kammler, R., Finn, S. P., Moch, H., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.09.014 · Cited by 7
Malignant Mesothelioma: Mechanism of Carcinogenesis
Kane, A. B., Jean, D., Knuutila, S., & Jaurand, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-30766-0_19 · Cited by 7
Antigen-specific immunotherapy in head and neck cancer
Hoffmann, T. K., & Schuler, P. J. (2013) · Advances in Cellular and Molecular Otolaryngology · doi:10.3402/acmo.v1i0.21758 · Cited by 7
Mutational signatures in squamous cell carcinoma of the lung
Osoegawa, A., Takada, K., Okamoto, T., Sato, S., Nagahashi, M., Tagawa, T., Tsuchida, M., Oki, E., Okuda, S., Wakai, T., et al. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-2602 · Cited by 7
Ninomiya, H., Kato, M., Sanada, M., Takeuchi, K., Inamura, K., Motoi, N., Nagano, H., Nomura, K., Sakao, Y., Okumura, S., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-8 · Cited by 7
Molecular Biology of Lung Preneoplasia
Kadara, H. N., & Wistuba, I. I. (2014) · Lung Cancer · doi:10.1002/9781118468791.ch6 · Cited by 7
[Personalized treatment in non-small cell lung cancer].
Campos-Parra, A. D., Cruz‐Rico, G., & Arrieta, O. G. (2012) · PubMed · Cited by 6
Personalizing Lung Cancer Prevention Through a Reverse Migration Strategy
Gold, K. A., Kim, E. S., Wistuba, I. I., & Hong, W. K. (2012) · Topics in current chemistry · doi:10.1007/128_2012_338 · Cited by 6
Gadgeel, S. M., & Kalemkerian, G. P. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0772-1_1 · Cited by 6
Chemical induced alterations in p53 signaling
Högberg, J., Silins, I., & Stenius, U. (2009) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-7643-8336-7_7 · Cited by 6
Lung cancer in non-smoking women (LCINSW): from risk factors to precision therapy
Zhao, J., Li, M., Niu, L., Zhao, Y., & Song, X. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10289-9 · Cited by 6
Meta-analysis reveals differences in somatic alterations by genetic ancestry across common cancers
Amuzu, S., Xie, A., Bai, X., Pekala, K. R., Pickersgill, N. A., Ma, D., Perea-Chamblee, T. E., Arora, K. S., Chatila, W. K., Derkach, A., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02371-3 · Cited by 6
Stead, L. F., Egan, P. A., Devery, A., Conway, C., Daly, C. L., Berri, S., Wood, H. M., Belvedere, O., Papagiannopoulos, K., Ryan, A. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078823 · Cited by 5
Specific intronicp53mutation in esophageal squamous cell carcinoma in Southern Thailand
Thongsuksai, P. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i42.5359 · Cited by 5
Agarwalla, P. K., Dunn, I. F., Turner, C. D., Ligon, K. L., Schneider, K. A., & Smith, E. R. (2008) · Pediatric Neurosurgery · doi:10.1159/000187125 · Cited by 4
Metadata
- Authors
- Le Calvez, F., Mukeria, A., Hunt, J. D., Kelm, O., Hung, R. J., Tanière, P., Brennan, P., Boffetta, P., Zaridze, D. G., & Hainaut, P.
- Affiliations
- 1IARC, Lyon, France;
- Russian Cancer Research Center NN Blokhin (RU)
- Centre international de recherche sur le cancer (FR)
- 4Department of Cellular Pathology, The Medical School, University of Birmingham, Egbaston, Birmingham, United Kingdom
- ORCID
- Venue
- Cancer Research
- Published
- 2005-06-15
- Volume
- 65
- Issue
- 12
- Pages
- 5076-5083
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2149459560
- Cited by
- 273
- References
- 54
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 8 · 2023: 12 · 2022: 11 · 2021: 12 · 2020: 9 · 2019: 15 · 2018: 4 · 2017: 10 · 2016: 11 · 2015: 9 · 2014: 11 · 2013: 14 · 2012: 27
- FWCI
- 13.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- European Commission (IC15-CT96-0313)
- National Institutes of Health (5k01es000358-03)
- National Institute of Environmental Health Sciences (K01‐ES00358)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- TP53 mutation, KRAS mutation, lung cancer, smoking, mutation patterns, G:C to T:A transversions, cyclooxygenase-2, nitrotyrosine, nitric oxide, inflammation, never smokers, former smokers, squamous cell carcinoma, adenocarcinoma, lung carcinogenesis
- MeSH terms
- Aged, Female, Humans, Immunohistochemistry, Lung Neoplasms, Male, Membrane Proteins, Middle Aged, Mutation, Prostaglandin-Endoperoxide Synthases, Genes, ras, Smoking, Tyrosine, Genes, p53, Tumor Suppressor Protein p53, Cyclooxygenase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
